EAU Bladder Cancer Recurrence Risk (EORTC)
EORTC-based risk stratification for non-muscle-invasive bladder cancer (NMIBC) recurrence and progression.
Score interpretation
EORTC 0–4: Low recurrence risk (~15% at 1 year)
→ Single instillation intravesical mitomycin C within 24h of TURBT; cystoscopy at 3 months, then annually if negative
EORTC 5–9: Intermediate recurrence risk (~38% at 1 year)
→ Adjuvant intravesical BCG or mitomycin C (6–12 inductions); cystoscopy at 3, 6, 12 months then annually
EORTC ≥10: High recurrence/progression risk
→ BCG induction + 1–3 year maintenance; consider radical cystectomy if T1G3 + CIS; cystoscopy every 3 months for 2 years
Interpretation bands for the Bladder Ca Risk. Apply clinical judgement and local guidance.
References
- Sylvester RJ, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables. Eur Urol. 2006;49(3):466-475.
Related
Curated clinical cross-links plus same-class fallbacks.
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Mirabegron (Overactive Bladder — Elderly) · Beta-3 Adrenoceptor Agonist
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Ziprasidone · Atypical Antipsychotic — D2/5-HT2A Antagonist (Low Metabolic Risk)
- Atorvastatin (CKD Cardiovascular Risk) · Cardiovascular Risk in CKD
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.